Principles of the treatment of peritoneal carcinomatosis due to colorectal cancer. Current review and update

Colorectal cancer is the most frequent digestive tumor. The incidence of abdominal dissemination is high and all studies of the natural history of colorectal carcinomatosis demonstrate that prognosis in these patients is poor, with a mean survival of between 5 and 9 months. Furthermore, the results...

Full description

Saved in:
Bibliographic Details
Published inCirugia Española Vol. 77; no. 1; p. 6
Main Authors Gómez-Portilla, Alberto, Cendoya, Iñaki, López de Tejada, Iñaki, Olabarria, Iñaki, Magrach, Luis, Martínez de Lecea, Concepción, Gil, Alberto, Valdovinos, Mercedes, Larrabide, Iñaki, Ruiz de Alegría, Natalia, Fernández, José Luis, Cachorro, Irune, Contreras, María del Carmen, Castañeda, Josu, Uriarte, Arantxa, Boado, María Victoria, Urturi, José Antonio, Ulibarrena, Miguel Angel
Format Journal Article
LanguageSpanish
Published Spain 01.01.2005
Subjects
Carcinoma - secondary
Carcinoma - therapy
Clinical Trials as Topic
Colorectal Neoplasms - pathology
Combined Modality Therapy
Humans
Peritoneal Neoplasms - secondary
Peritoneal Neoplasms - therapy
Online AccessGet more information

Cover

More Information
Summary:Colorectal cancer is the most frequent digestive tumor. The incidence of abdominal dissemination is high and all studies of the natural history of colorectal carcinomatosis demonstrate that prognosis in these patients is poor, with a mean survival of between 5 and 9 months. Furthermore, the results of systemic adjuvant treatment are disappointing, with a maximum survival of 18 months. Consequently, other treatment strategies need to be studied and developed. We present a review of the principles that underlie Sugarbakers treatment protocol, which includes maximal cytoreductive surgery for the treatment of macroscopic disease through peritonectomy together with perioperative intraperitoneal intensification chemotherapy for residual microscopic disease. We present all the phase II studies with more than 10 treated patients published in the medical literature by the main groups working in this line of treatment, together with the only phase III study published to date. With this new therapeutic alternative, the mean overall survival at 2 and 5 years is 40% and 20% respectively. Based on these results, this new therapeutic approach is recommended as the treatment of choice in these unfortunate patients. The limits of the treatment of advanced colorectal cancer are also discussed.
ISSN:0009-739X